CAMBRIDGE, England, January 20, 2026--biomodal, an omics-based life sciences technology and analytics company, today announced the publication of a study in Nature Communications Medicine showcasing ...
A Sex-specific View on Atherosclerosis From molecular plaque insights to innovative diagnostics ...
Zacks Small Cap Research on MSN
YDES: YD Biopharma is an integrated biotechnology company that is poised to have a transformational year as it expands business operations
YDES YD Bio (NASDAQ:YDES) is an integrated biotechnology company that combines diagnostics, precision medicine, and regenerative ophthalmology under a single commercial and development strategy. The ...
American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a ...
The multi-modal approach leverages additional information from the patient's tumor sample, using Natera's AI models trained on long-term molecular and clinical outcomes from Natera's proprietary ...
An Abuja-based medical expert, Dr Maryam Ahmed Almustapha, has raised an alarm over the potentially devastating effects of ...
BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the selection of ...
GraftAssure technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian siteGraftAssureDx FDA IVD approval application 95% complete at yea ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback